Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
grade D 161.08 1.35% 2.15
GLPG closed up 1.35 percent on Friday, September 20, 2019, on 62 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical GLPG trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 1.35%
Multiple of Ten Bearish Other 1.88%
Outside Day Range Expansion 1.88%
Oversold Stochastic Weakness 1.88%
NR7 Range Contraction 1.02%
Oversold Stochastic Weakness 1.02%
Stochastic Reached Oversold Weakness 1.69%

Older signals for GLPG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Medicine Medical Specialties Immunology Autoimmune Diseases Monoclonal Antibodies Inflammation Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Osteoarthritis Inflammatory Diseases Ulcerative Colitis Arthritis Abdominal Pain Colitis Treatment Of Inflammatory Diseases Sle Treatment Of Inflammation
Is GLPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 191.63
52 Week Low 85.0
Average Volume 195,274
200-Day Moving Average 124.6886
50-Day Moving Average 169.297
20-Day Moving Average 163.0345
10-Day Moving Average 159.832
Average True Range 3.0946
ADX 25.38
+DI 16.0307
-DI 27.124
Chandelier Exit (Long, 3 ATRs ) 161.3562
Chandelier Exit (Short, 3 ATRs ) 166.5638
Upper Bollinger Band 170.7214
Lower Bollinger Band 155.3476
Percent B (%b) 0.37
BandWidth 9.429783
MACD Line -2.0613
MACD Signal Line -1.6487
MACD Histogram -0.4127
Fundamentals Value
Market Cap 8.19 Billion
Num Shares 50.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -230.11
Price-to-Sales 23.11
Price-to-Book 3.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 164.59
Resistance 3 (R3) 164.48 163.20 164.01
Resistance 2 (R2) 163.20 162.31 163.26 163.81
Resistance 1 (R1) 162.14 161.75 162.67 162.25 163.61
Pivot Point 160.86 160.86 161.13 160.92 160.86
Support 1 (S1) 159.80 159.97 160.33 159.91 158.55
Support 2 (S2) 158.52 159.41 158.58 158.35
Support 3 (S3) 157.46 158.52 158.16
Support 4 (S4) 157.57